Agenus director Garo Armen paid in company stock
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received 4,852 shares of common stock on July 10, 2026 as a grant in lieu of cash salary. The shares represent the net amount of his salary for that pay period, are issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and are fully vested on the date of issuance. The share amount is based on the $3.35 closing price of Agenus common stock on July 10, 2026. Following this award, Armen holds 371,108 shares directly, plus additional indirect holdings through IRA accounts and trust and partnership entities.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 4,852 shares
Grant/Award
3 txns
Insider
ARMEN GARO H
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 4,852 | $3.35 | $16K |
| holding | Common Stock F3 | -- | -- | -- |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 371,108 shares (Direct);
Common Stock — 60,248 shares (Indirect, See Footnote)
Footnotes (4)
- F1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 10th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
- F2. $3.35 is the closing price of our Common Stock on July 10th, 2026, the last trading day for the payroll date for the pay period ending July 10th, 2026.
- F3. Shares are held in Dr. Armen's IRA accounts.
- F4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Key Figures
Stock grant shares: 4852.0000 shares
Stock grant reference price: $3.35 per share
Direct holdings after grant: 371108.0000 shares
+3 more
6 metrics
Stock grant shares
4852.0000 shares
Common stock awarded in lieu of cash salary for pay period ending July 10, 2026
Stock grant reference price
$3.35 per share
Closing price of Agenus common stock on July 10, 2026 used to determine the grant
Direct holdings after grant
371108.0000 shares
Direct Agenus common stock owned by Garo H. Armen following the reported award
Indirect IRA holdings
31298.0000 shares
Indirect Agenus common stock held in Dr. Armen’s IRA accounts
GRAT holdings
23,950 shares
Shares of Agenus common stock held by the Garo Armen 2020 2 Year AG GRAT
Pixie Partners holdings
5,000 shares
Agenus common stock owned by Pixie Partners, in which Armen is a general partner
Key Terms
Equity Incentive, GRAT, pecuniary interest, closing price
4 terms
Equity Incentive financial
"issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive"
Equity incentive is a form of pay that gives employees or executives a stake in the company through stock or the right to buy stock, often granted with conditions that spread out over time. It matters to investors because it aligns workers’ interests with shareholders—encouraging growth and retention—but can also affect share count and profits when new shares are issued, similar to giving team members a slice of the company pie that can grow or dilute others’ slices.
GRAT financial
"Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock"
pecuniary interest financial
"Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie"
closing price financial
"$3.35 is the closing price of our Common Stock on July 10th, 2026"
FAQ
What insider transaction did Garo H. Armen report for Agenus (AGEN)?
Garo H. Armen reported receiving 4,852 shares of Agenus common stock as compensation for his salary, paid in stock instead of cash for the pay period ending July 10, 2026. These shares are fully vested and issued under the company’s 2019 Equity Incentive plan.
At what price was the Agenus (AGEN) stock salary for Garo H. Armen calculated?
The stock salary was calculated using the $3.35 closing price of Agenus common stock on July 10, 2026. This date was the last trading day for the payroll date covering the pay period ending July 10, 2026, and determined the number of shares issued.
How is Garo H. Armen’s salary structured at Agenus (AGEN) according to this filing?
At his request and with Compensation Committee approval, Garo H. Armen’s salary is paid in stock instead of cash. The 4,852 shares reported represent the net amount of his salary for the pay period ending July 10, 2026, issued fully vested under the 2019 Equity Incentive plan.
Does this Agenus (AGEN) Form 4 reflect any open-market buying or selling by Garo H. Armen?
The reported activity reflects a stock grant in lieu of salary, not open-market trading. The Form 4 shows a grant of 4,852 fully vested shares based on the closing price, plus updated indirect holdings, with no open-market purchases or sales indicated in the structured data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
